What medspa spending data says about weight-loss and wellness services

Who this is for

This is for the physician or medical professional who owns an aesthetic practice or medspa and has been pitched IV therapy, a weight-loss program or another wellness line, and for the operations lead who would price it.

The pitch sells visits: more reasons for a patient to come in, and to come more often. Each visit is also a checkout. A vitamin shot rung up on its own counts as one transaction, the same as a syringe of filler, so a practice can gain visits and still see its average transaction value fall.

What do Zenoti's $484 and AmSpa's $536 medspa benchmarks measure?

Two published benchmarks put a dollar amount on one medspa transaction. One comes from a company that sells software to medspas, the other from their trade association, and they measure different things.

A Zenoti pricing guide cites the company's 2026 Beauty and Wellness Benchmark Report for a 90th percentile medspa ticket of $484, meaning one transaction; 90% of measured values fall below it, and the page does not say whether those values were single tickets or each location's average.¹

Zenoti writes that the gap between its median ticket and its 90th percentile is "explained almost entirely by pricing strategy and service mix," and rules out location, equipment and clinical skill. Service mix is what a wellness line changes. The claim comes from a vendor whose software sets and tracks those prices.¹

The guide's pricing method starts from cost: a price set to hold a 60 to 70% gross margin, checked against local prices, then tuned to what it calls the practice's "positioning tier." On that method a wellness service is priced from its own cost, whatever the practice's average ticket.¹

The American Med Spa Association (AmSpa), the trade group, reported that patients spent $536 per visit on average in 2022, across an average of 283 nonsurgical patient visits a month. That is an average per visit from a survey; Zenoti's is a percentile of tickets. AmSpa does not say whether one visit is one transaction.²

AmSpa's own revenue numbers shift between editions: $1,982,896 average annual revenue in its 2022 summary, then $1,307,587 rising to $1,398,833 in its 2024 report, which does not say whether that is per business or per location. The 2024 report reads the rise as demand that "continues to grow" as medspas multiply. A practice that compares itself to one edition is comparing against numbers that change between editions.^2,3

Neither Zenoti's guide nor AmSpa's summaries gives a price for any single wellness service. Whether an IV drip or a weight-loss visit sits above or below a practice's average ticket comes down to that practice's own price list.

What have Kline and Qsight reported about weight loss and wellness at aesthetic practices?

Two research firms report wellness growing at aesthetic practices by different methods: Kline asks consumers, Qsight models sales.

Kline, a market research firm, reported that the average number of procedures a consumer had in a year fell to 3.1 in 2023 from 3.7 in 2022. It tied the drop to tighter budgets, with "spending on services shifting toward lower spending tiers for non-invasive aesthetic treatments and skin care products." It does not define the tiers.⁴

In the same summary, Kline says wellness supplements and IV hydration drips "have surged in terms of popularity" with the same consumers. So in one report, patients had fewer procedures while wellness gained. Kline does not say whether one took the other's place.⁴

Qsight, Guidepoint's market-data service, works from projected sales. Its April 2025 report says weight-loss and dietary lifestyle treatments made up 12% of the spending it models for nonsurgical patients at aesthetic practices in 2024, up significantly since 2021. That is a share of the money, so it shows where spending moved and says nothing about the size of each checkout.⁵

The same report puts patient spending on GLP-1 medications, the class that includes semaglutide and tirzepatide, at US aesthetic practices at $0.74 billion in 2023 and $1.30 billion in 2024. Qsight counts physician offices along with medspas, so a surgeon's office is inside that market.⁵

How many UK adults who paid for weight-loss treatments expect to pay again?

One survey here asks about expected repeat spending. In it, weight-loss treatment came out ahead of every other private treatment it covered, cosmetic treatment included.

CACI, a UK data and research firm, polled 2,000 UK adults for its H1 Voice of the Nation survey. The share who expected to pay for weight-loss treatments rose to 15% for 2026, from 13% in 2025. The share who expected to pay for cosmetic treatments fell to 12% for 2026, from 14% in 2025. CACI's post does not say whether weight-loss treatments means drugs, programs or visits.⁶

Of the people who paid for weight-loss treatments in 2025, 67% expected to pay again in 2026. CACI calls this "the highest repeat spending observed in the data among different types of private treatment," and says Gen Z and millennials are driving demand. That is the repeat behavior a wellness pitch promises, measured here as stated intent.⁶

The sample is British, and UK patients buy private treatment alongside a public health service, so the shares do not transfer directly to a US medspa.

The one peer-reviewed study in this review, a 2020 Aesthetic Surgery Journal report on 3,785 patients who bought skin-care products, is about retail skin care. Neither it nor CACI measures cross-sell: what a wellness patient later spends on aesthetic treatment at the same practice.⁷

Average transaction value counts one checkout, and lifetime value counts what a patient spends with the practice over time. A wellness pitch built on visits is an argument about lifetime value, and CACI's 67% supports it only as stated UK intent.

A weight-loss offer also brings a different patient into the practice, one who comes for a medical program and starts with a prescription conversation. What that patient costs to acquire, and whether they go on to book an aesthetic treatment, are numbers only the practice holds.

What has the FDA said about compounded GLP-1 drugs that medspas sell?

Qsight reports GLP-1 spending at aesthetic practices growing from 2023 to 2024, and some practices offer compounded versions of those drugs in their weight-loss lines. The FDA issued warning letters to Expert Aesthetics in 2025 and to Kin Meds and ProRx LLC in 2026.^5,8,9,10

A compounded drug is one that a pharmacy or outsourcing facility prepares itself. The FDA says it does not review compounded drugs for safety, effectiveness or quality.¹¹

The FDA has a page on unapproved GLP-1 drugs used for weight loss. On it, the agency says adverse events from compounded versions are underreported, and that many of those reported for compounded products appear consistent with adverse events tied to the approved versions. The page keeps a running count of reports, updated as of May 31, 2026.¹¹

The neurotoxins and fillers most aesthetic practices already buy are FDA-approved products, and compounded GLP-1 drugs are not reviewed by the FDA. Our reading, from that statement, is that a practice offering a compounded drug relies on its compounder for the drug's quality.

Which wellness numbers sit only in a practice's own records?

None of the sources reports average transaction value by service line, how soon each kind of patient rebooks, how many wellness patients go on to book an aesthetic treatment, or provider and room time per visit for each line. Each sits in a practice's own records.

Provider and room time shape staffing: a weight-loss program uses a prescriber's time, and an IV drip occupies a chair for the length of the infusion. What a service earns depends on its ticket and on that time together.

A practice's overhead, its fee for each service and its patient mix belong to the practice, and none of the sources estimates them.

About this review

We read eleven sources in October 2026: two AmSpa survey reports, a Zenoti pricing guide, a Kline report summary, a CACI survey post, a Qsight report, a peer-reviewed paper and four FDA pages (one safety page and three warning letters). Data points from different publishers appear side by side, and no gap or ratio is computed between them.

The Aesthetic Surgery Journal study was read through a research tool's summary, and the article uses only its patient count; its results in Canadian dollars are left out for that reason. The article takes only each recipient's name and year from the three FDA warning letters.

None of the sources prices a single wellness service, and none reports average transaction value split between aesthetic and wellness visits. CACI's survey covers UK adults, and Qsight's data points are projections from sales data.

Fractional Aesthetics is a growth strategy practice for aesthetic medical businesses.